PET-like scan using a special protein in lung cancer
Part of Cancer, Lungs & breathing clinical trials.
This Phase 2 study tests whether a new imaging medicine (a radiopharmaceutical) can highlight immune cells called macrophages in people with non-small cell lung cancer. It may help doctors better “see” and evaluate tumor tissue before a surgical biopsy or removal.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are at least 18 years old and can give informed consent.
- You have non-small cell lung cancer that is local, locally advanced, or metastatic.
- You are scheduled for surgery to remove or biopsy at least one tumor or lymph node.
- The lesion to be sampled is large enough (about 10 mm or more in the specified direction).
- You are well enough to do study activities (ECOG 0–2), not needing intensive care-level support.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a special PET scan (68Ga-grazytracer) to see if it can predict early whether immunotherapy is working in people with lung cancer that can be surgically removed. If successful, this scan could help doctors tailor treatment sooner.
This trial tests a new type of PET scan that uses a special tracer to find lung tumors. The goal is to see if this scan can better detect cancer cells, which may help doctors plan the best treatment for you.
This study uses a PET scan with a special radioactive tracer (68Ga-DOTA-Siglec-9) to look at cancer in certain people. It may help doctors better see cancer-related activity and guide treatment planning for selected cancers.
This study uses a special PET/CT scan to better tell if a lung nodule is non-small cell lung cancer. If you have a solid nodule in your lung that's at least 8 mm and might be cancer, this scan could help get a clearer diagnosis.
This trial tests a new imaging agent (68Ga-FL-031) to see if it can help find and stage tumors in people with small cell lung cancer, breast cancer, nasopharyngeal cancer, or other cancers. The goal is to improve diagnosis and treatment planning.
This trial tests a new targeted radioactive drug that seeks out a specific marker on lung cancer cells. It first uses a low-dose imaging scan to see if the cancer cells have this marker, then gives a higher-dose treatment to destroy those cells.
Hear when a new Non Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.